- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SIENTRA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 282,90 | +2,19 % | Wichtige Termine! LVMH, UnitedHealth, Meta, Strategy, Bitcoin im Check | Die Aktienmärkte haben eine schwache Handelswoche hinter sich. Sowohl der DAX als auch die großen US-Indizes gaben in der vergangenen Woche deutlich ab. Immerhin macht die Wall Street mit ihrer Performance... ► Artikel lesen | |
| TELADOC HEALTH | 6,363 | +0,78 % | Does Teladoc's Acquisition Strategy Boost Growth and Global Footprint? | ||
| THERMO FISHER | 513,60 | +0,98 % | Thermo Fisher Scientific Subsidiary Prices EUR 2.1 Bln Senior Notes Offering | HONG KONG (dpa-AFX) - Thermo Fisher Scientific Inc. (TMO) has priced an offering of 2.1 billion euros aggregate principal amount of euro-denominated notes, to be issued by Thermo Fisher Scientific... ► Artikel lesen | |
| ROKU | 81,96 | +0,94 % | Access Advance Applauds Historic Preliminary Injunction in German HEVC Enforcement Action Against Roku | BOSTON, MA / ACCESS Newswire / November 24, 2025 / Access Advance LLC today announced that one of its Licensors, Dolby International AB, has obtained a historic preliminary injunction from the Landgericht... ► Artikel lesen | |
| RESMED | 221,80 | +2,02 % | RESMED INC: Ceasing to be a Director/Section 16 Officer | ||
| ATOSSA THERAPEUTICS | 0,641 | -2,14 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update | Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities... ► Artikel lesen | |
| HENRY SCHEIN | 65,04 | +0,68 % | Biomerica, Inc.: Biomerica's inFoods IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| ZIMMER BIOMET | 83,24 | +2,59 % | Zimmer Biomet Announces FDA Clearance For Enhanced Version Of ROSA Knee System | SEOUL (dpa-AFX) - Zimmer Biomet Holdings, Inc. (ZBH) announced FDA 510(k) clearance of ROSA Knee with OptimiZe, an enhanced version of its ROSA Knee System. Zimmer Biomet will conduct a targeted... ► Artikel lesen | |
| PETMED EXPRESS | 1,408 | -1,44 % | PetMed Express, Inc.: PetMeds Files Form 10-K for Fiscal 2025 | DELRAY BEACH, Fla., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the "Company") dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today filed with the Securities and Exchange Commission... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced | BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| TANDEM DIABETES | 18,860 | +1,23 % | Tandem Diabetes Care beruft Sandra Beaver in den Verwaltungsrat | ||
| ASENSUS SURGICAL | - | - | GlobalLogic, Asensus ink surgical robotics engineering collab | ||
| QUIDELORTHO | 24,000 | +3,45 % | QuidelOrtho Corporation: QuidelOrtho Reports Third Quarter 2025 Financial Results | ? Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ? ... ► Artikel lesen | |
| VERU | 2,410 | +2,99 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen |
SIENTRA INC gehört der Branche Gesundheitswesen an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIENTRA INC finden Sie auf Wallstreet Online.